Time to nursing home admission and death in people with dementia: systematic review and meta-analysis.

Chiara C Br��ck, Sanne S Mooldijk, Lieke M Kuiper, Muhammed L Sambou, Silvan Licher, Francesco Mattace-Raso, Frank J Wolters
Author Information
  1. Chiara C Br��ck: Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, Netherlands.
  2. Sanne S Mooldijk: Department of Epidemiology, Erasmus MC University Medical Centre, Rotterdam, Netherlands.
  3. Lieke M Kuiper: Department of Internal Medicine, Erasmus MC University Medical Centre, Rotterdam, Netherlands.
  4. Muhammed L Sambou: Department of Epidemiology, Erasmus MC University Medical Centre, Rotterdam, Netherlands.
  5. Silvan Licher: Department of Epidemiology, Erasmus MC University Medical Centre, Rotterdam, Netherlands.
  6. Francesco Mattace-Raso: Department of Internal Medicine, Erasmus MC University Medical Centre, Rotterdam, Netherlands.
  7. Frank J Wolters: Department of Epidemiology, Erasmus MC University Medical Centre, Rotterdam, Netherlands f.j.wolters@erasmusmc.nl. ORCID

Abstract

OBJECTIVE: To summarise available evidence on time to nursing home admission and death among people with dementia, and to explore prognostic indicators.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, Web of Science, Cochrane, and Google Scholar from inception to 4 July 2024.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Longitudinal studies on survival or nursing home admission in people with dementia. Studies with fewer than 150 participants, recruitment during acute hospital admission, or less than one year of follow-up were excluded.
RESULTS: 19���307 articles were identified and 261 eligible studies included. 235 reported on survival among 5���553���960 participants and 79 reported on nursing home admission among 352���990 participants. Median survival from diagnosis appeared to be strongly dependent on age, ranging from 8.9 years at mean age 60 for women to 2.2 years at mean age 85 for men. Women overall had shorter survival than men (mean difference 4.1 years (95% confidence interval 2.1 to 6.1)), which was attributable to later age at diagnosis in women. Median survival was 1.2 to 1.4 years longer in Asia than in the US and Europe, and 1.4 years longer for Alzheimer's disease compared with other types of dementia. Compared with studies before 2000, survival was longer in contemporary clinic based studies (P=0.02), but not in community based studies. Taken together, variation in reported clinical characteristics and study methodology explained 51% of heterogeneity in survival. Median time to nursing home admission was 3.3 years (interquartile range 1.9 to 4.0). 13% of people were admitted in the first year after diagnosis, increasing to 57% at five years, but few studies appropriately accounted for competing mortality risk when assessing admission rates.
CONCLUSIONS: The average life expectancy of people with dementia at time of diagnosis ranged from 5.7 years at age 65 to 2.2 at age 85 in men and from 8.0 to 4.5, respectively, in women. About one third of remaining life expectancy was lived in nursing homes, with more than half of people moving to a nursing home within five years after a dementia diagnosis. Prognosis after a dementia diagnosis is highly dependent on personal and clinical characteristics, offering potential for individualised prognostic information and care planning.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022341507.

References

  1. JAMA Neurol. 2021 Oct 1;78(10):1255-1261 [PMID: 34491284]
  2. PLoS One. 2020 Jan 14;15(1):e0227742 [PMID: 31935267]
  3. Alzheimers Res Ther. 2016 Jul 30;8(1):23 [PMID: 27473681]
  4. Int J Epidemiol. 2007 Jun;36(3):666-76 [PMID: 17470488]
  5. Stat Med. 2021 Aug 30;40(19):4200-4212 [PMID: 33969508]
  6. Transl Psychiatry. 2024 Apr 10;14(1):184 [PMID: 38600070]
  7. Dement Geriatr Cogn Disord. 2008;26(1):65-78 [PMID: 18617737]
  8. Brain Inform. 2016 Jun;3(2):119-131 [PMID: 27747607]
  9. Ageing Res Rev. 2019 Mar;50:72-80 [PMID: 30625375]
  10. Lancet Healthy Longev. 2021 Aug;2(8):e479-e488 [PMID: 36097997]
  11. PLoS One. 2020 Dec 4;15(12):e0243513 [PMID: 33275638]
  12. Neurology. 2012 May 8;78(19):1456-63 [PMID: 22551732]
  13. Int J Geriatr Psychiatry. 2013 Nov;28(11):1109-24 [PMID: 23526458]
  14. Int Psychogeriatr. 2012 Jul;24(7):1034-45 [PMID: 22325331]
  15. Syst Rev. 2024 Mar 1;13(1):81 [PMID: 38429798]
  16. Nat Rev Neurol. 2017 Jun;13(6):327-339 [PMID: 28497805]
  17. Eur J Epidemiol. 2022 Aug;37(8):807-814 [PMID: 35731313]
  18. Int J Surg. 2021 Apr;88:105906 [PMID: 33789826]
  19. N Engl J Med. 2016 Feb 11;374(6):523-32 [PMID: 26863354]
  20. J Am Med Dir Assoc. 2009 Sep;10(7):466-71 [PMID: 19716062]
  21. Alzheimers Dement. 2023 Apr;19(4):1598-1695 [PMID: 36918389]
  22. Alzheimers Dement (N Y). 2021 Aug 20;7(1):e12189 [PMID: 34458555]

MeSH Term

Humans
Nursing Homes
Dementia
Male
Aged
Time Factors
Female
Patient Admission
Aged, 80 and over
Prognosis

Word Cloud

Created with Highcharts 10.0.0yearsnursingadmissionsurvival1homepeopledementia4studiesdiagnosisage2timeamongparticipantsreportedMedianmeanwomenmenlongerdeathprognosticreviewmeta-analysisoneyeardependent8985basedclinicalcharacteristics30fivelifeexpectancy5OBJECTIVE:summariseavailableevidenceexploreindicatorsDESIGN:SystematicDATASOURCES:MedlineEmbaseWebScienceCochraneGoogleScholarinceptionJuly2024ELIGIBILITYCRITERIAFORSELECTINGSTUDIES:LongitudinalStudiesfewer150recruitmentacutehospitallessfollow-upexcludedRESULTS:19���307articlesidentified261eligibleincluded2355���553���96079352���990appearedstronglyranging60Womenoverallshorterdifference95%confidenceinterval6attributablelaterAsiaUSEuropeAlzheimer'sdiseasecomparedtypesCompared2000contemporaryclinicP=002communityTakentogethervariationstudymethodologyexplained51%heterogeneityinterquartilerange13%admittedfirstincreasing57%appropriatelyaccountedcompetingmortalityriskassessingratesCONCLUSIONS:averageranged765respectivelythirdremaininglivedhomeshalfmovingwithinPrognosishighlypersonalofferingpotentialindividualisedinformationcareplanningSYSTEMATICREVIEWREGISTRATION:PROSPEROCRD42022341507Timedementia:systematic

Similar Articles

Cited By

No available data.